Compare GSK plc (GSK) vs Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? GSK plc trades at $52.4 (market cap $101.34B), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $28.85. The key difference: GSK plc pays a 3.49% dividend while Roundhill Russell 2000 0DTE Covered Call Strat ETF pays none, and GSK plc is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| GSK | RDTE | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $61.18 | $34.72 |
52-Week Low | $36.20 | $26.40 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
RDTE trades at $28.90, up 0.63% with a bearish technical signal from moving averages. The stock shows no valuation or profitability metrics available, but has a history of frequent small dividend payments. Recent news highlights structural risks in its covered call strategy, contributing to negative sentiment.
Outlook remains cautious due to capital erosion risks from the ETF's strategy capping upside. Investment opportunity is limited by lack of fundamental data and bearish technicals. Key risks include NAV deterioration and inability to capture market rallies, warranting careful evaluation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →
